| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| EP2360254A1 (en) | 1999-08-23 | 2011-08-24 | Dana-Farber Cancer Institute, Inc. | Assays for screening anti-pd-1 antibodies and uses thereof |
| EP1283851B1 (en) | 2000-05-26 | 2012-03-28 | Immunex Corporation | Use of il-4r antibodies and compositions thereof |
| DK2206517T3 (en) | 2002-07-03 | 2023-11-06 | Ono Pharmaceutical Co | Immunopotentiating compositions comprising anti-PD-L1 antibodies |
| US7488802B2 (en) | 2002-12-23 | 2009-02-10 | Wyeth | Antibodies against PD-1 |
| GB0407315D0 (en) | 2003-07-15 | 2004-05-05 | Cambridge Antibody Tech | Human antibody molecules |
| GEP20104991B (en) | 2003-11-07 | 2010-05-25 | Immunex Corp | Antibodies that bind interleukin-4 receptor |
| JP4851944B2 (en) | 2003-12-23 | 2012-01-11 | ジェネンテック， インコーポレイテッド | Novel anti-IL13 antibody and use thereof |
| US7501121B2 (en) | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
| TWI307630B (en) | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
| AR050044A1 (en) | 2004-08-03 | 2006-09-20 | Novartis Ag | IL-4 SPECIFIC ANTIBODY |
| CA3151350A1 (en) | 2005-05-09 | 2006-11-16 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| WO2006124451A2 (en) | 2005-05-11 | 2006-11-23 | Centocor, Inc. | Anti-il-13 antibodies, compositions, methods and uses |
| CA3201163A1 (en) | 2005-07-01 | 2007-01-11 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| KR101461263B1 (en) | 2005-10-21 | 2014-11-17 | 노파르티스 아게 | Human antibodies against IL-13 and therapeutic uses |
| WO2007107349A1 (en) | 2006-03-22 | 2007-09-27 | Apogenix Gmbh | Antibody specific for human il-4 for the treament of cancer |
| BRPI0716438B1 (en) | 2006-09-08 | 2022-01-25 | Abbvie Bahamas Ltd | il-13 binding proteins, recombinant anti-il-13 antibody, antibody construct, pharmaceutical compositions and uses thereof to reduce il-13 biological activity and function and treat respiratory disorders |
| UA98943C2 (en) | 2006-10-02 | 2012-07-10 | Ридженерон Фармасьютикалз, Инк. | High affinity human antibodies to human il-4 receptor |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| CN102131828B (en) | 2007-06-18 | 2015-06-17 | 默沙东有限责任公司 | Antibody against human programmed death receptor PD-1 |
| EP2050764A1 (en) | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
| CA2706419A1 (en) | 2007-11-30 | 2009-06-04 | Glaxo Group Limited | Antigen-binding constructs binding il-13 |
| US8092804B2 (en) | 2007-12-21 | 2012-01-10 | Medimmune Limited | Binding members for interleukin-4 receptor alpha (IL-4Rα)-173 |
| US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
| EP2927240A1 (en) | 2008-08-25 | 2015-10-07 | Amplimmune, Inc. | Compositions of pd-1 antagonists and methods of use |
| AU2009296392B2 (en) | 2008-09-26 | 2016-06-02 | Dana-Farber Cancer Institute, Inc. | Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor |
| PT4209510T (en) | 2008-12-09 | 2024-04-02 | Hoffmann La Roche | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| GB0904214D0 (en) | 2009-03-11 | 2009-04-22 | Ucb Pharma Sa | Biological products |
| PH12013500672A1 (en) | 2010-10-06 | 2013-06-03 | Regeneron Pharma | Stabilized formulations containing anti-interleukin-4-receptor (il-4r) antibodies |
| DK2627673T3 (en) | 2010-10-15 | 2017-11-06 | Medimmune Ltd | THERAPY TO IMPROVE LUNGE FUNCTION |
| RU2604814C2 (en) | 2011-07-24 | 2016-12-10 | Кьюртек Лтд. | Versions of humanized immunomodulatory monoclonal antibodies |
| AU2012344260B2 (en) | 2011-11-28 | 2017-09-07 | Merck Patent Gmbh | Anti-PD-L1 antibodies and uses thereof |
| HK1204557A1 (en) | 2012-05-31 | 2015-11-27 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind pd-l1 |
| CN104271601B (en) | 2012-05-31 | 2020-02-04 | 霍夫曼-拉罗奇有限公司 | Methods of treating cancer using PD-1 axis binding antagonists and VEGF antagonists |
| JP6306588B2 (en)* | 2012-08-21 | 2018-04-04 | サノフィ・バイオテクノロジー | Method for treating or preventing asthma by administering an IL-4R antagonist |
| DK2904011T3 (en)* | 2012-10-02 | 2017-12-04 | Bristol Myers Squibb Co | COMBINATION OF ANTI-KIR ANTIBODIES AND ANTI-PD-1 ANTIBODIES FOR TREATMENT OF CANCER |
| US9308236B2 (en) | 2013-03-15 | 2016-04-12 | Bristol-Myers Squibb Company | Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions |
| RU2015141529A (en) | 2013-04-05 | 2017-05-15 | Дженентек, Инк. | ANTIBODIES AND SPECIFIC ANTIBODIES TO IL-4 AND THEIR APPLICATION |
| RU2674680C2 (en)* | 2013-06-21 | 2018-12-12 | Санофи Байотекнолоджи | Methods for treating nasal polyposis by administering il-4r antagonist |
| TWI680138B (en) | 2014-01-23 | 2019-12-21 | 美商再生元醫藥公司 | Human antibodies to pd-l1 |
| TWI681969B (en) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | Human antibodies to pd-1 |
| KR20160120735A (en)* | 2014-02-28 | 2016-10-18 | 리제너론 파아마슈티컬스, 인크. | Methods for treating skin infection by administering an il-4r antagonist |
| EP3177649B1 (en) | 2014-08-05 | 2024-02-28 | Apollomics Inc. | Anti-pd-l1 antibodies |
| KR20170135860A (en) | 2015-03-13 | 2017-12-08 | 싸이톰스 테라퓨틱스, 인크. | Anti-PD1 antibodies, activatable anti-PD1 antibodies, and methods of using them |
| MX383464B (en) | 2015-07-13 | 2025-03-14 | Cytomx Therapeutics Inc | ANTI-PD-1 ANTIBODIES, ACTIVATABLE ANTI-PD-1 ANTIBODIES, AND METHODS OF USING THE SAME. |
| WO2017019896A1 (en)* | 2015-07-29 | 2017-02-02 | Novartis Ag | Combination therapies comprising antibody molecules to pd-1 |
| AR105654A1 (en) | 2015-08-24 | 2017-10-25 | Lilly Co Eli | ANTIBODIES PD-L1 (LINKING 1 OF PROGRAMMED CELL DEATH) |
| TWI756187B (en)* | 2015-10-09 | 2022-03-01 | 美商再生元醫藥公司 | Anti-lag3 antibodies and uses thereof |
| EP4420733A3 (en)* | 2016-02-19 | 2024-12-11 | Regeneron Pharmaceuticals, Inc. | Methods for enhancing efficacy of a vaccine by administering an il-4 antagonist |
| JP7539231B2 (en) | 2016-04-07 | 2024-08-23 | ケモセントリクス，インコーポレーテッド | Reduction of tumor burden by administering a CCR1 antagonist in combination with a PD-1 inhibitor or a PD-L1 inhibitor |
| CN110536905B (en) | 2017-02-21 | 2023-10-27 | 瑞泽恩制药公司 | Anti-PD-1 antibodies for lung cancer treatment |
| US11603407B2 (en) | 2017-04-06 | 2023-03-14 | Regeneron Pharmaceuticals, Inc. | Stable antibody formulation |
| TWI799432B (en)* | 2017-07-27 | 2023-04-21 | 美商再生元醫藥公司 | Anti-ctla-4 antibodies and uses thereof |
| WO2019051204A1 (en) | 2017-09-08 | 2019-03-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Synergistic combination of il4 receptor targeted agents, interferon gamma, and interferon alpha for use in treating ovarian cancer |
| WO2021062332A1 (en)* | 2019-09-27 | 2021-04-01 | Icahn School Of Medicine At Mount Sinai | Combination of inhibitors of il4 signaling and immune checkpoints for treating cancer |
| US20240336688A1 (en)* | 2021-07-22 | 2024-10-10 | Icahn School Of Medicine At Mount Sinai | Dual-blockade of il-4 signaling and immune checkpoint proteins for treating cancer |